Contents

Search

ceritinib; pelitinib (Zykadia)

Indications: - metastatic non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase positive, previously treated with crizotinib Adverse effects: - diarrhea, nausea, vomiting, abdominal pain - increased lserum transaminases - increased serum amylase & serum lipase - increased serum glucose Mechanism of action: - inhibits anaplastic lymphoma kinase (ALK)

Interactions

drug adverse effects of tyrosine kinase inhibitor(s)

General

small inhibitory antineoplastic agent (ib drug) antineoplastic tyrosine kinase inhibitor

Database Correlations

PUBCHEM correlations

References

  1. FDA News Release: April 29, 2014 FDA approves Zykadia for late-stage lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395299.htm